MENU

ABOUT US

NEWS

Announcement of New Chief Technology Officer (CTO): Pro. Yoshiki Sawa

2021/09/03

Tokyo, Japan (August 13, 2021) – CUORiPS Inc. (HQ: Chuo-ku, Tokyo; President: Takayuki Kusanagi) is pleased to announce the appointment of Professor Yoshiki Sawa (Osaka University Graduate School of Medicine, Division of Health Sciences, Future Medical Science) as its new Chief Technology Officer (CTO), effective August 13, 2021.

Under the new organization with Pro. Yoshiki Sawa, we will further accelerate the commercialization of First-In-Human allogeneic iPS cell-derived cardiomyocyte cell sheets with Osaka University and the creation of innovative cell therapy products for Heart Failure by promoting our R&D with diverse partners.

Curriculum Vitae of Dr. Sawa
1980Graduated from Osaka University Medical School and received MD
1987Received a PhD from Osaka University Medical School
1989Research and clinical fellow at Max-Planck Institute in Germany supported by Humboldt Scholarship (~1991)
1992Assistant Professor, Department of Cardiovascular Surgery,
Osaka University Medical School
1998   Associate Professor, Department of Cardiovascular Surgery,
Osaka University Medical School
2002Associate Professor, Medical Center for Translational Research
in Osaka University Graduate School of Medicine
2004Chief surgeon, Department of Cardiovascular Surgery
2006 Professor and Chief, Department of Cardiovascular Surgery
Director, Medical Center for Translational Research in Osaka
University Hospital (~Mar. 2010)
2010 Director, Center for Medical, Engineering, and Information in
Osaka University (~Mar. 2015)
2013Vice Dean, Osaka University Graduate School of Medicine
(~Mar. 2015) Director,
Center for Global Health in Osaka University Hospital (~Mar. 2015)
2014 Adviser, CiRA(Center for iPS cell Research and Application)
Kyoto University
2015 Dean, Osaka University Graduate School of Medicine (~Mar. 2017) President, Japanese Society of Regenerative Medicine (~Mar. 2021)
2016Congress Chairman, Japanese Surgical Society
2018Congress Chairman, The Japanese Circulation Society
Congress Chairman, Tissue Engineering and Regenerative
Medicine International Society World Congress
2019President of Japanese Association for Thoracic Surgery (~Present)
2020Council member, Science Council of Japan
2021Professor, Division of Health Sciences, Future Medical Science,
Osaka University Graduate School of Medicine
Awards & Honors:
l  Humboldt Scholarship
l  Terumo Foundation Grant
l  METI Grant
l  Japan Biomaterial Association Award
l  Scientific Technology Award sponsored by Minister of Education, Culture, Sports, Science, and Technology
l  Medal with Purple Ribbon from the Emperor of Japan

The new management structure as of August 13, 2021 will be as follows:

President and CEOTakayuki Kusanagi
COOManabu Inoue
Director of the Board and CTOYoshiki Sawa
Director of the Board and CFOTaichi Kobayashi
External Board MemberTetsuya Ohira
External Board MemberRyohei Shimazaki

About CUORiPS Inc.

CUORiPS Inc. is a start-up company, established in March 2017, based on technology and research results of Osaka University, for the development and commercialization of iPS cell-derived cardiomyocyte sheets.

CUORiPS is developing production process technology of iPS cell-derived cardiomyocyte sheets to increase efficiency, and to obtain Japanese government approval as the world’s 1st regenerative medicine for severe heart failures.

About iPS cell-derived cardiomyocyte sheets

An allogeneic cell therapeutic product mainly composed of cardiomyocytes (iPS myocardium), differentiated from human iPS cells is processed into a sheet and will be transplanted onto the surface of the patient’s heart. Therapeutic effects such as improvement of heart function and recovery of heart failure can be expected to the patients with severe heart failure such have no treatment options.